CD7 CAR-T cell therapy

**CD7 CAR-T cell therapy** is a form of adoptive cell therapy where T cells are engineered ex vivo to express a chimeric antigen receptor (CAR) targeting CD7, a transmembrane glycoprotein highly expressed on most T-cell lymphoblastic leukemias and lymphomas as well as normal T cells and NK cells[7][1][5]. The engineered CAR T cells are designed to recognize and kill malignant cells expressing CD7. To prevent fratricide (CAR-T cells killing each other due to CD7 expression on normal T cells), gene editing or protein retention strategies are often used to abrogate CD7 surface expression in the engineered cells[1][7]. This therapy has shown high remission rates in relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), with studies encompassing both autologous (patient-derived) and allogeneic (donor-derived, "off-the-shelf") approaches[1][2][3][5][7]. Major developers include academic institutions and biotechnology companies advancing products like CTD402[2]. Frequent adverse events include cytokine release syndrome and mild neurotoxicity[1][5][7].

Other names

CD7 chimeric antigen receptor T-cell therapyCD-7 chimeric antigen receptor T-cell therapyCD 7 chimeric antigen receptor T-cell therapyanti-CD7 CAR-T cell therapyanti-CD-7 CAR-T cell therapyanti-CD 7 CAR-T cell therapy